7.81
+0.05(+0.64%)
Currency In USD
Address
One Main Street
Cambridge, MA 02142
United States of America
Phone
617 410 4650
Sector
Healthcare
Industry
Biotechnology
Employees
111
First IPO Date
January 08, 2021
| Name | Title | Pay | Year Born |
| Mr. Nadim Ahmed | President, Chief Executive Officer & Director | 1.17M | 1968 |
| Ms. Mary Kay Fenton CPA | Chief Financial Officer | 544,153 | 1964 |
| Dr. Patrick A. Baeuerle Ph.D. | Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board | 763,734 | 1958 |
| Dr. Jeffrey Jones M.B.A., M.D., M.P.H. | Chief Medical Officer | 844,826 | 1971 |
| Mr. Kevin A. Johnston | Chief Technical Operations Officer | 0 | N/A |
| Mr. Steve Andre | Chief Human Resources Officer | 0 | N/A |
| Ms. Rose Weldon | Senior Vice President of Corporate Affairs | 0 | N/A |
| Ms. Jacquelyn L. Sumer J.D. | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | 0 | 1978 |
| Dr. Corinne Savill Ph.D. | Chief Business Officer | 0 | 1959 |
| Dr. Jennifer Michaelson Ph.D. | Chief Scientific Officer | 0 | 1967 |
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.